Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BioXcel Therapeutics, Inc. BTAI
$27.01
-$0.06 (-0.24%)
На 18:00, 12 мая 2023
+81.41%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
783256500.00000000
-
week52high
34.13
-
week52low
8.80
-
Revenue
375000
-
P/E TTM
-4
-
Beta
1.10415200
-
EPS
-5.91000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 12:00
Описание компании
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 24 авг 2022 г. |
| Mizuho | Buy | 07 июл 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 23 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 14 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 14 мар 2022 г. |
| Mizuho | Buy | Buy | 16 ноя 2022 г. |
| Mizuho | Buy | Buy | 11 ноя 2022 г. |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
| Canaccord Genuity | Buy | Buy | 11 ноя 2022 г. |
| Goldman Sachs | Neutral | Sell | 01 дек 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 янв 2023 г. |
| Goldman Sachs | Neutral | Neutral | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Yocca Frank | D | 8397 | 50000 | 20 янв 2023 г. |
| O'Neill Vincent | D | 29712 | 29713 | 20 янв 2023 г. |
| O'Neill Vincent | D | 0 | 29713 | 20 янв 2023 г. |
| O'Neill Vincent | A | 29713 | 29713 | 20 янв 2023 г. |
| Nandabalan Krishnan | D | 354000 | 25889 | 05 янв 2023 г. |
| Nandabalan Krishnan | D | 0 | 800 | 05 янв 2023 г. |
| Nandabalan Krishnan | D | 800 | 25089 | 05 янв 2023 г. |
| Nandabalan Krishnan | A | 25889 | 25889 | 05 янв 2023 г. |
| Nandabalan Krishnan | D | 379889 | 34111 | 04 янв 2023 г. |
| Nandabalan Krishnan | D | 0 | 9821 | 04 янв 2023 г. |
Новостная лента
Why These 3 Nasdaq Stocks Were Glowing Green This Week
The Motley Fool
11 мая 2023 г. в 15:13
A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.
Why BioXcel Therapeutics Stock Marched Higher Today
The Motley Fool
08 мая 2023 г. в 16:54
BioXcel Therapeutics announced 2023 first-quarter earnings today. While revenue for the three-month period wasn't a needle-mover, investors appear to be intrigued by a series of upcoming trial readouts.
BioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 14:48
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Rob Risinger - Chief Medical Officer, Neuroscience Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Mary Kate - Bank of America Colin Bristow - UBS Yatin Suneja - Guggenheim Partners Sumant Kulkarni - Canaccord Genuity Ram Selvaraju - H.C. Wainwright Operator Good morning, and welcome to the BioXcel Therapeutics First Quarter 2023 Financial Results Conference Call.
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
GlobeNewsWire
02 мая 2023 г. в 07:00
NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at 10:15 a.m. PT. He will be joined by Robert Risinger, M.D., Chief Medical Officer, Neuroscience, and Matt Wiley, Chief Commercial Officer.
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating
Seeking Alpha
26 апр 2023 г. в 19:33
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating.